Thoracic research

We are the largest respiratory and respiratory oncology research group in Western Australia’s private health sector.

Our research extends across respiratory and thoracic oncology, spanning primary lung malignancy, interstitial lung disease, mesothelioma, pulmonary hypertension, pulmonary thromboembolic disease, respiratory complications of connective tissue disorders and respiratory issues in bariatric surgery.
 
  • 1 in 17 Australians are at risk of developing lung cancer.
  • Lung cancer is the leading cause of cancer death in Australia. 
  • Approximately 200 new patients are diagnosed with lung cancer at St John of God Subiaco Hospital every year.
 
  • The collection of biospecimens and clinical data from patients with known or suspected thoracic malignancies, facilitating future research which may lead to earlier detection of disease in patients. 
  • Annual appointment of Research Fellows interested in respiratory medicine and respiratory oncology to provide them with an opportunity to gain valuable skills and experience in research.
 
Consultants
Professor Eli Gabbay
Dr Tim Clay

Research nurses
Nisha Sikotra
Tara Hannon

Bendat Research Fellows
Dr Ashley Tan
Dr Rohen Skiba
Dr Phil Craven
Dr Ciara Daly
 
Craven, P., Daly, C., Sikotra, N., Clay, T., Gabbay, E. Dilemmas in anticoagulation and use of Inferior Vena Cava Filters (IVCFs) in Venous Thrombo-Embolism (VTE); a survey of Respiratory Physicians, Haematologists and Medical Oncologists [Submitted to Journal]

Skiba, R., Sikotra, N., Ball, T, Arellano, A., Gabbay, E., Clay, T.D (2019) Management of Febrile Neutropenia in a Private Hospital Oncology Unit. Internal Medicine Journal [in press].

Skiba,R., Sikotra, R., Wilson, A., Clay, T.D., Gabbay, E. A survey of doctors to assess their current practice and understanding of consent law [Submitted to Journal]

Sikotra, N., Daly, C., Craven,P., Gabbay, E., Clay, T.D. Establishment of the WA Thoracic Research Group Biospecimen Bank [Submitted to Journal]

Clay, T.D., Craven, P., Gabbay E. Warfarin is not the anticoagulant of choice for malignancy-associated venous thromboembolism [Letter] (2019) Internal Medical Journal 49 (7): p934 https://doi.org/10.1111/imj.14343
 

You may be interested in